Atropine dry-powder inhalation - MicroDose Therapeutx

Drug Profile

Atropine dry-powder inhalation - MicroDose Therapeutx

Alternative Names: Atropine sulfate dry-powder inhalation - MicroDose Therapeutx; MDT-010

Latest Information Update: 24 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MicroDose Therapeutx
  • Class Alkaloids; Small molecules; Tropanes
  • Mechanism of Action Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Poisoning

Most Recent Events

  • 24 Mar 2016 No recent reports on development identified - Phase-I for Poisoning (In volunteers) in USA (Inhalation)
  • 08 Jul 2013 MicroDose Therapeutx has been acquired by Teva Pharmaceutical Industries
  • 24 Sep 2009 Phase-I clinical trials in Poisoning in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top